Company profile
OMEROS CORP
NASDAQ:OMERBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| YARTEMLEA | approved | $9.9MQ1 2026 | 0 | — |
| NARSOPLIMAB | phase3 | — | 4 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (24)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02132312 | phase3 | completed | 2014-07-01 | 2016-09-12 | Omeros Corporation | A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement |
| NCT00624845 | phase2_3 | completed | 2007-12-01 | 2009-05-01 | Omeros Corporation | Double-Blind, Multicenter, Study Comparing the Efficacy and Safety of OMS103HP With Vehicle Irrigation Solution in Subjects Undergoing Meniscectomy |
| NCT05855083 | phase2 | recruiting | 2023-05-01 | 2025-12-01 | Omeros Corporation | Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA |
| NCT00226759 | phase3 | completed | 2004-11-01 | 2010-09-01 | Omeros Corporation | Efficacy and Safety of OMS103HP in Patients Undergoing Allograft Anterior Cruciate Ligament (ACL) Reconstruction |
| NCT00226772 | phase3 | completed | 2005-06-01 | 2010-09-01 | Omeros Corporation | Efficacy and Safety of OMS103HP in Patients Undergoing Autograft Anterior Cruciate Ligament (ACL) Reconstruction |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 761152 | 2025-12-23 | BLA | OMEROS CORPORATION | |||||
Loading… | ||||||||